Germany · Delayed Price · Currency is EUR SCHOTT Pharma AG & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw revenue up 4.8% at constant currencies and EBITDA margin rise to 27.1%, driven by strong demand for high-value solutions. Guidance for FY 2026 is maintained, with expected revenue growth of 2%-5% and continued investment in capacity expansion.
Fiscal Year 2025
-
Revenue grew 3% to EUR 986 million in 2025, with high-value solutions at 57% of sales and EBITDA margin up to 28.4%. 2026 guidance anticipates 2%-5% revenue growth and a 27% EBITDA margin, with GLP-1 and specialty vials as key drivers amid lower mRNA and vaccine demand.
-
Q3 revenue grew 3% year-over-year to €256 million, with EBITDA up 11% to €83 million and a record 31.7% margin, driven by high-value solutions. FY2025 guidance is for 6% organic revenue growth and a 28% EBITDA margin, with continued investment in capacity and innovation.
-
Q2 2025 saw revenues rise 8% year-on-year to EUR 252 million, with EBITDA up 63% and a margin of 28.6%, driven by strong HVS demand. Full-year guidance is maintained amid market volatility, with CapEx reduced and limited tariff impact expected.
-
Q1 2025 saw stable revenues of EUR 230 million, with strong HVS demand and robust order intake in vials, especially in EMEA and North America. EBITDA margin was 26.3% at constant currencies, and full-year guidance for high single-digit revenue growth and stable margins is confirmed.
Fiscal Year 2024
-
Delivered strong revenue and profitability in 2024, with high-value solutions driving growth and new long-term contracts signed, especially in GLP-1. 2025 guidance calls for high single-digit revenue growth, stable margins, and back-end loaded performance as new capacities ramp up.
-
Q3 saw record revenue and EBITDA growth, driven by strong DDS demand and capacity expansion, with HVS share reaching 53%. Full-year revenue guidance was raised to 11%-13%, and robust market trends in GLP-1, mRNA, and ADCs support a positive outlook.